[Transurethral laser ablation of the prostate (TULAP). Initial results with 188 patients].
Laser therapy for benign prostatic hyperplasia (BPH) is now the most impressive alternative to transurethral resection of the prostate (TUR-P). Transurethral laser ablation of the prostate (TULAP) is a new technique that combines non-contact and contact laser treatment of BPH. From November 1992 to August 1994, 188 patients were treated by the TULAP technique. Their median age was 70.3 (58-87) years. The mean prostatic volume determined by transrectal ultrasound, was 49.2 ml. A 6-month follow up was possible for 102 patients. The AUA 7-Symptom Score decreased from 29 points preoperatively to 6 points after 6 months. Residual urine volume decreased from 205 ml to 27 ml after 6 months. Maximum flow rate increased from 7.2 ml/s to 19.3 ml/s after 6 months. No severe complications were observed, and in particular no major bleeding or TUR syndrome. We regard the TULAP procedure as an effective treatment alternative for obstructive symptoms caused by BPH.
Gottfried
H W
HW
Urologische Universitätsklinik Ulm.
Krautschick
A
A
Hefty
R
R
Weber
H M
HM
Frohneberg
D
D
Hautmann
R E
RE
D000368:Aged; D000369:Aged, 80 and over; D020684:Cystoscopes; D004867:Equipment Design; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000000981:diagnostic imaging; D011468:Prostatectomy / Q000295:instrumentation*; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000601:surgery*; D016896:Treatment Outcome; D014463:Ultrasonography; D001748:Urinary Bladder Neck Obstruction / Q000000981:diagnostic imaging / Q000601:surgery*; D014563:Urodynamics / Q000502:physiology